AbbVie Inc. – FDA CRL, Apr 22, 2026

The FDA issued a Complete Response Letter to AbbVie Inc. on April 22, 2026, regarding the Biologics License Application (BLA 761459) for AGN-151586 for injection. This notice indicates that the application cannot be approved in its current form due to several critical deficiencies that must be addressed. A primary obstacle involves unresolved issues identified during a pre-license inspection of the manufacturing facility. The facility must provide satisfactory responses to these findings before the FDA can proceed with approval. Additionally, the FDA requires a comprehensive safety update, including data from all clinical and nonclinical trials, detailed narratives of serious adverse events, and a summary of worldwide safety experience. The agency also reserved final comments on product labeling and the proposed brand name until the substantive issues are resolved. Under the regulatory framework of 21 CFR 601.3, AbbVie is required to take action within one year by submitting a complete response that addresses all cited deficiencies. Required actions include coordinating with the manufacturing site to resolve inspection findings, updating the Medication Guide with specific pharmacist instructions, and providing a thorough re-tabulation of patient safety data. Failure to respond within the one-year timeframe may result in the FDA considering the application withdrawn.